<?xml version="1.0" encoding="UTF-8"?>
<p id="par0100">Ling Li et al., added CP in addition to standard therapy in 103 Covid-19 patients. The trial was conducted in open, multicentric randomized 7 centers in China. CP and standard therapy were applied to 52 patients and standard therapy was performed to 51 patients. Improvement in CP treatment group was 51.9 %, improvement in standard treatment group was 43.1 %, and this difference was statistically nonsignificant (hazard ratio, 1.40, p 0.26). There was no significant difference in mortality rates between two groups [
 <xref rid="bib0085" ref-type="bibr">17</xref>].
</p>
